The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β-arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.
本发明部分提供了公式I的化合物:及其药学上可接受的盐和N-氧化物;其制备的过程和中间体;以及其组合物和用途。本发明进一步提供具有减少D1R脱敏作用的D1激动剂,具有相对于
多巴胺减少β-阻滞素招募活性的D1激动剂,当结合到D1R时与Ser188显著相互作用但与Ser202显著相互作用较少的D1激动剂,与D1R结合时与Asp103相互作用较弱且与Ser198相互作用较弱的D1激动剂及其用途。